Back to MPT Database

mAb 2C7 + TDF IVR

mAb 2C7 and TDF will be formulated into IVRs. mAb 2C7 will have activity against gonorrhea and TDF will target HIV.

Development Stage:

Preclinical – Advanced (Pre2)

Hormonal/Non-Hormonal:

Non-Contraceptive

Delivery Route & Method:

Topical - Intravaginal Ring (IVR)

Mechanism of Action:

mAb 2C7 mediates complement-dependent killing of Neisseria gonorrhoeae. TDF is NRTI targeting HIV infection.

Developer:

  • MassBiologics
  • Oak Crest Institute of Science
  • Planet Biotechnology, Inc.
  • University of Massachusetts

Funding:

  • Nat. Institute Allergy & Infect. Diseases (NIAID)

Funding Mechanism:

NIAID: R33

Past Funding:

NIAID: R33, U19

Active Ingredient(s):

  • Monoclonal Antibodies
  • Tenofovir Disoproxil Fumarate (TDF)

Product Indication(s):

  • Gonorrhea
  • HIV

Back to MPT Database